NAV

Spartalizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Spartalizumab
DrugBank Accession Number
DB14892
Background

Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).

Type
Biotech
Groups
Investigational
Synonyms
  • Spartalizumab
External IDs
  • PDR001

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UProgrammed cell death protein 1
inhibitor
antibody
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QOG25L6Z8Z
CAS number
1935694-88-4

References

General References
Not Available
Wikipedia
Spartalizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentMelanoma1
3RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Pancreatic Metastatic Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of Prostate / Adenocarcinoma of the Lung / Anal Carcinoma / Bladder Carcinoma / Carcinoma of Unknown Primary / Cervical Carcinoma / Cholangiocarcinoma / Clear Cell Renal Cell Carcinoma / Colorectal Adenocarcinoma (CRC) / Endometrial Carcinoma / Esophageal Squamous Cell Carcinoma (ESCC) / Esophagus Adenocarcinoma / Gastric Adenocarcinoma / Hepatocellular Carcinoma / HER2/Neu-positive Breast Cancer / Hormone Receptor Positive (HR+), HER2-negative Breast Cancer / Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation / Melanoma / Mesotheliomas / Microsatellite Instability High Colorectal Cancer / Other Histology / Ovarian Serous Cystadenocarcinoma / Pancreatic Adenocarcinoma / Sarcomas / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Lung Cancer / Thyroid Carcinoma / Triple-Negative Breast Cancer / Uterine Carcinosarcoma / Uveal Melanoma1
2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Head And Neck Cancer / Melanoma / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Microsatellite Stable (MSS) Colorectal Cancer (CRC) / Non-Small Cell Lung Cancer (NSCLC) / Pancreatic Cancer / Renal Cell Carcinoma (RCC) / Triple-Negative Breast Cancer / Urothelial Cancer1
2Active Not RecruitingTreatmentGastric Cancer by AJCC V8 Stage / Resectable Carcinoma1
2Active Not RecruitingTreatmentHistologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment1
2Active Not RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma (PDAC)1
2Active Not RecruitingTreatmentPathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
2CompletedTreatmentAdenocarcinoma of the Ovaries / Advanced Well-differentiated Neuroendocrine Tumors / Castration Resistant Prostate Adenocarcinoma / Diffuse Large B-Cell Lymphoma (DLBCL) / Esophagus Adenocarcinoma / Gastric Adenocarcinoma / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma1
2CompletedTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Programmed cell death protein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Antibody
General Function
Signal transducer activity
Specific Function
Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. ...
Gene Name
PDCD1
Uniprot ID
Q15116
Uniprot Name
Programmed cell death protein 1
Molecular Weight
31646.635 Da

Drug created at May 20, 2019 14:33 / Updated at February 21, 2021 18:55